Notice: Proposed Modification to Bioequivalence Standards for Multiphasic Modified-Release Drug Products (English, HTML)

View metadata and access the original English HTML file: Notice: Proposed Modification to Bioequivalence Standards for Multiphasic Modified-Release Drug Products.

Format

HTML

Access

file-only

Publisher-reported update

2023-12-24

This Notice serves to inform sponsors of drug submissions pursuant to Division C.08 of the Food and Drug Regulations (i.e., new drug and abbreviated new drug submissions), of proposed modifications to Health Canada’s comparative bioavailability requirements when multiphasic plasma concentration profiles have been demonstrated to be integral to the product’s therapeutic effect.

Access original file